Tesaglitazar

Tesaglitazar (AZ 242) is a peroxisome proliferator-activated receptor agonist with affinity to PPARα and PPARγ, proposed for type 2 diabetes.[1]

The drug had completed several phase III clinical trials,[2] however in May, 2006 AstraZeneca announced that it had discontinued further development.[3]

References